Blackwell Jonathan, Selinger Christian, Raine Tim, Parkes Gareth, Smith Melissa A, Pollok Richard
Department of Gastroenterology, St George's Hospitals NHS Foundation Trust, London, UK.
School of Public Health, Imperial College London, London, UK.
Frontline Gastroenterol. 2020 Apr 2;12(3):207-213. doi: 10.1136/flgastro-2019-101288. eCollection 2021.
Corticosteroids remain an important tool for inducing remission in inflammatory bowel disease (IBD) but they have no role in maintenance of remission. The significant adverse side effect profile of these drugs means their use should be avoided where possible or measures taken to reduce their risk. Despite an expanding array of alternative therapies, corticosteroid dependency and excess remain common. Appropriate steroid use is now regarded a key performance indicator in the management of IBD. This article aims to outline indications for corticosteroid use in IBD, their risks and strategies to reduce their use and misuse.
皮质类固醇仍然是诱导炎症性肠病（IBD）缓解的重要工具，但它们在维持缓解方面没有作用。这些药物显著的不良副作用意味着应尽可能避免使用它们，或采取措施降低风险。尽管替代疗法不断增加，但皮质类固醇依赖和过量使用仍然很常见。现在，合理使用类固醇被视为IBD管理中的一项关键绩效指标。本文旨在概述IBD中使用皮质类固醇的适应症、风险以及减少其使用和滥用的策略。
